Portfolio: Investments By Stage
As the current collection demonstrates, MPM is committed to participating and succeeding across the life-cycle spectrum of companies. We invest in companies that range from research to commercial, with an emphasis on early-stage human proof-of-concept assets. MPM's portfolio consists of over 150 drugs and 23 devices in development or in the market. We have assembled a team with world-class capabilities across the continuum from research to commercial.
MPM Biotech Portfolio (by stage of development)
MPM Medtech Portfolio (by stage of development)
